Skip to main content
Equibles
ANGO logo

ANGO · Angiodynamics Inc · Webcasts, Transcripts & Audio

Track ANGO — free

Use ANGO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANGO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.54 +0.43 (+2.85%)
Russell 2000 member Rebalance outlook locked
Market Cap
$627.84M
Shares
42.05M
Volume · Oct 5 636.19K Avg daily vol (3M) 496.13K

Angiodynamics Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Angiodynamics Inc (ANGO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲13.2% $87.00M −$13.00M '22 Q4 22-07-12 ▲9.1% $85.43M −$8.49M '23 Q2 23-01-05 ▲9.1% $80.71M −$9.48M '23 Q3 23-03-30 ▲4.7% $91.07M −$21.47M '23 Q4 23-07-12 ▼3.5% $78.68M $45.88M '24 Q1 23-10-04 ▼7.4% $79.07M −$29.05M '24 Q2 24-01-05 ▼6.9% $75.18M −$187.74M '24 Q3 24-04-04 ▼14.2% $67.49M −$12.80M '25 Q1 24-10-03 ▼7.9% $72.84M −$10.74M '25 Q2 25-01-08 ▼4.2% $72.00M −$4.41M '25 Q3 25-04-02 ▲12.9% $80.16M −$6.05M '25 Q4 25-07-15 ▲12.2% $75.71M −$10.90M '26 Q1 25-10-02 ▲9% $79.43M −$6.35M '26 Q2 26-01-06 ▲8.9% $78.42M −$8.08M '26 Q3 26-04-02 LATEST ▲8% $86.61M −$11.40M '26 Q4 26-07-14
Earnings call
FY27 · Q1
2026-10-08
Angiodynamics Inc (ANGO) Q1 2027 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-08-11
Angiodynamics Inc (ANGO) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q4
2026-07-14
Angiodynamics Inc (ANGO) Q4 2026 Earnings Call Transcript
Confident tone MedTech growth and portfolio transformation Mechanical thrombectomy (AlphaVac, AngioVac) NanoKnife prostate growth and reimbursement
Revenue
$86.61M*
▲ 8% YoY
Gross margin
54.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-06-10
Angiodynamics Inc (ANGO) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-04-14
Angiodynamics Inc (ANGO) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-04-02
Angiodynamics Inc (ANGO) Q3 2026 Earnings Call Transcript
Confident tone Mechanical thrombectomy (Alphavac/AngioVac) NanoKnife and CPT-1 reimbursement Sterilization shutdown supply-chain headwind
Revenue
$78.42M
▲ 8.9% YoY
Diluted EPS
$-0.19
Gross margin
52.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-09
Angiodynamics Inc (ANGO) March 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-01-14
Angiodynamics Inc (ANGO) January 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-01-06
Angiodynamics Inc (ANGO) Q2 2026 Earnings Call Transcript
Confident tone Mechanical thrombectomy platform Auryon growth and international expansion NanoKnife prostate opportunity and CPT code
Revenue
$79.43M
▲ 9% YoY
Diluted EPS
$-0.15
Gross margin
56.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-10-02
Angiodynamics Inc (ANGO) Q1 2026 Earnings Call Transcript
Confident tone Med Tech segment growth and acceleration Mechanical Thrombectomy (AlphaVac / AngioVac) NanoKnife prostate indication and reimbursement
Revenue
$75.71M
▲ 12.2% YoY
Diluted EPS
$-0.26
Gross margin
55.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-07-15
Angiodynamics Inc (ANGO) Q4 2025 Earnings Call Transcript
Confident tone MedTech Portfolio Growth Mechanical Thrombectomy (AlphaVac / AngioVac) Auryon Peripheral Atherectomy
Revenue
$80.16M*
▲ 12.9% YoY
Gross margin
52.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-04-02
Angiodynamics Inc (ANGO) Q3 2025 Earnings Call Transcript
Confident tone MedTech segment growth and raised guidance Mechanical Thrombectomy (AlphaVac and AngioVac) Med Device segment return to growth
Revenue
$72.00M
▼ 4.2% YoY
Diluted EPS
$-0.11
Gross margin
54.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-01-08
Angiodynamics Inc (ANGO) Q2 2025 Earnings Call Transcript
Confident tone Mechanical thrombectomy (AlphaVac and AngioVac) NanoKnife prostate program Guidance and profitability outlook
Revenue
$72.84M
▼ 7.9% YoY
Diluted EPS
$-0.26
Gross margin
54.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-10-03
Angiodynamics Inc (ANGO) Q1 2025 Earnings Call Transcript
Positive tone MedTech growth drivers (Auryon, AlphaVac, NanoKnife) Full-year fiscal 2025 guidance Discontinued/divested businesses and comparisons
Revenue
$67.49M
▼ 14.2% YoY
Diluted EPS
$-0.31
▼ 127% YoY
Gross margin
54.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-04-04
Angiodynamics Inc (ANGO) Q3 2024 Earnings Call Transcript
Confident tone Portfolio optimization and divestitures Med tech segment growth AlphaVac FDA approval for PE
Revenue
$75.18M
▼ 6.9% YoY
Diluted EPS
$-4.67
Gross margin
47.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-01-05
Angiodynamics Inc (ANGO) Q2 2024 Earnings Call Transcript
Balanced tone Mechanical Thrombectomy (AngioVac / AlphaVac) International Business Auryon Platform
Revenue
$79.07M
▼ 7.4% YoY
Diluted EPS
$-0.72
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-10-04
Angiodynamics Inc (ANGO) Q1 2024 Earnings Call Transcript
Revenue
$78.68M
▼ 3.5% YoY
Diluted EPS
$1.15
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-07-12
Angiodynamics Inc (ANGO) Q4 2023 Earnings Call Transcript
Revenue
$91.07M*
▲ 4.7% YoY
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-03-30
Angiodynamics Inc (ANGO) Q3 2023 Earnings Call Transcript
Revenue
$80.71M
▲ 9.1% YoY
Diluted EPS
$-0.24
Gross margin
50.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-01-05
Angiodynamics Inc (ANGO) Q2 2023 Earnings Call Transcript
Revenue
$85.43M
▲ 9.1% YoY
Diluted EPS
$-0.21
Gross margin
52.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-07-12
Angiodynamics Inc (ANGO) Q4 2022 Earnings Call Transcript
Revenue
$87.00M*
▲ 13.2% YoY
Gross margin
53.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-04-07
Angiodynamics Inc (ANGO) Q3 2022 Earnings Call Transcript
Revenue
$73.97M
▲ 3.9% YoY
Diluted EPS
$-0.13
Gross margin
52.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-01-06
Angiodynamics Inc (ANGO) Q2 2022 Earnings Call Transcript
Revenue
$78.28M
▲ 7.6% YoY
Diluted EPS
$-0.21
Gross margin
51.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-09-30
Angiodynamics Inc (ANGO) Q1 2022 Earnings Call Transcript
Revenue
$76.97M
▲ 9.6% YoY
Diluted EPS
$-0.18
Gross margin
52.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-07-13
Angiodynamics Inc (ANGO) Q4 2021 Earnings Call Transcript
Revenue
$76.84M*
▲ 31.7% YoY
Gross margin
55.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-03-30
Angiodynamics Inc (ANGO) Q3 2021 Earnings Call Transcript
Revenue
$71.18M
▲ 2% YoY
Diluted EPS
$-0.09
Gross margin
54.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-01-07
Angiodynamics Inc (ANGO) Q2 2021 Earnings Call Transcript
Revenue
$72.77M
▲ 4% YoY
Diluted EPS
$-0.11
Gross margin
55.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-09-29
Angiodynamics Inc (ANGO) Q1 2021 Earnings Call Transcript
Revenue
$70.22M
▲ 6.3% YoY
Diluted EPS
$-0.11
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-07-16
Angiodynamics Inc (ANGO) Q4 2020 Earnings Call Transcript
Revenue
$58.33M
▼ 18.1% YoY
Diluted EPS
$-4.14
▼ 368.8% YoY
Gross margin
51.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-04-07
Angiodynamics Inc (ANGO) Q3 2020 Earnings Call Transcript
Revenue
$69.78M
▲ 6.5% YoY
Diluted EPS
$-0.15
▼ 850% YoY
Gross margin
57.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-01-07
Angiodynamics Inc (ANGO) Q2 2020 Earnings Call Transcript
Revenue
$70.00M
▲ 0% YoY
Diluted EPS
$-0.07
▼ 216.7% YoY
Gross margin
59.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2019-08-31
Angiodynamics Inc (ANGO) Q1 2020 Earnings Call Transcript
Revenue
$66.04M
▲ 3.3% YoY
Diluted EPS
$-0.03
Gross margin
57.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–32 of 32 webcasts
Key facts CIK 1275187 CUSIP 03475V101 13F (30d) 4 filings 4 filers Visit website Investor relations